US · Healthcare · Biotechnology
EPS came in at -1.11 against a street estimate of -0.98 — a miss of 13.3%.
Analysts rate Ideaya Biosciences Inc a strong buy (12 buy, 1 hold, 0 sell out of 13) with an average price target of $53.54.
| Fund | Stake |
|---|---|
| FMR Inc | 14.99% |
| BlackRock Inc | 9.61% |
| HHG PLC | 8.27% |
| Capital Research Global Investors | 5.88% |
| Baker Bros Advisors LP | 4.49% |
| State Street Corp | 4.30% |
| Vanguard Capital Management, LLC | 4.25% |
| Logos Global Management LP | 3.93% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-23 |
| Company announcement · Q2 2026 | 2026-06-10 |
| Company announcement · Q2 2026 | 2026-06-03 |
| Reg FD disclosure · Q2 2026 | 2026-06-01 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-29 |
| Annual report FY2025 | 2026-02-17 |
| Quarterly report · Q3 2025 | 2025-11-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ideaya Biosciences Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.